Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Phase 2 portion To estimate the distribution of best HI, based on IWG 2006 criteria in patients with very low-, low-, and intermediate-risk MDS by IPSS-R treated with LY2157299 plus best supportive care. This includes a broad range of responses (see secondary objectives). Phase 3 portion To compare the percentage of patients with very low-, low-, and intermediate-risk MDS by IPSS-R when treated with LY2157299 versus placebo, in combination with best supportive care, who are transfusion-free or have a rise of ≥1.5 g/dL Hb maintained for at least 8 weeks within the first 24 weeks of treatment.
Critère d'inclusion
- Myelodysplastic syndromes